XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Patent and Technology License Agreements (Details) - USD ($)
1 Months Ended 6 Months Ended
Sep. 30, 2021
Jan. 31, 2023
Jun. 30, 2022
Jan. 31, 2022
Jun. 30, 2021
Mar. 31, 2023
Patent and Technology License Agreements (Details) [Line Items]            
Maintenance fee   $ 75,000 $ 90,000 $ 60,000 $ 90,000  
Royalty payment           $ 100,000
Increasing annual royalties           25,000
Maximum aggregate annual royalties           150,000
Payable amount to NAT           1,100,000
Milestone payments           $ 2,100,000
Agreement expiration date           Jan. 02, 2034
Developmental milestones payment           $ 51,000,000
Revenue percentage           50.00%
License agreement development, description           Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a biologics license application (“BLA”) for I/ONTAK.
Extension fee           $ 10,000,000
Minimum [Member]            
Patent and Technology License Agreements (Details) [Line Items]            
Maintenance fee           15,000
Royalty payment           100,000
Maximum [Member]            
Patent and Technology License Agreements (Details) [Line Items]            
Maintenance fee           90,000
Royalty payment           $ 25,000
Novellus Inc [Member]            
Patent and Technology License Agreements (Details) [Line Items]            
Research and development expense $ 5,000,000          
Outstanding equity 25.00%          
Percentage of outstanding equity           75.00%
Percentage of ownership additional shares           25.00%